PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.

Novartis’ NVS phase III study showed a positive risk-benefit profile of an investigational gene therapy candidate, intrathecal onasemnogene abeparvovec (OAV101 IT), for treating spinal muscular ...

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...

CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and ...

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...

Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments ...

The party is over for national chain Party City, which will be shuttering doors on hundreds of stores across the US, ...

Shopify is the IBD Stock of the Day. The e-commerce company has several initiatives underway that could provide upside for ...

U.S. stock futures were stalling early Tuesday as the market grapples with possible repercussions from any tariffs imposed by ...